Andrew J. Piper-Vallillo

Oncology

1 Essex Center Drive
Peabody, MA 01960

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

The emerging role for induction chemoimmunotherapy in unresectable stage III NSCLC: A promising approach in need of a definitive phase III trial.

The emerging role for induction chemoimmunotherapy in unresectable stage III NSCLC: A promising approach in need of a definitive phase III trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 24, 2026

Safety and efficacy of osimertinib 160 mg daily given concurrently with a strong CYP3A4 inducer.

Safety and efficacy of osimertinib 160 mg daily given concurrently with a strong CYP3A4 inducer.

Journal: Respiratory medicine case reports

Published: December 02, 2024

Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.

Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 08, 2024

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.

Journal: The oncologist

Published: April 18, 2024

Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.

Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and Partnership.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 27, 2024

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.

Journal: Cancers

Published: January 31, 2024

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.

Journal: JTO clinical and research reports

Published: October 27, 2022

Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer.

Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 15, 2022

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.

Journal: JTO clinical and research reports

Published: February 21, 2022

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.

Journal: Clinical lung cancer

Published: August 30, 2021

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 30, 2020

Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19.

Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19.

Journal: The oncologist

Published: December 19, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026